<DOC>
	<DOCNO>NCT01010568</DOCNO>
	<brief_summary>The purpose study evaluate safety effectiveness combination bendamustine ofatumumab subject relapsed/refractory chronic lymphocytic leukemia small cell lymphoma . All subject enrol study receive drug intravenous ( IV ) infusion .</brief_summary>
	<brief_title>Ofatumumab Bendamustine Previously Treated Chronic Lymphocytic Leukemia ( CLL )</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Bendamustine Hydrochloride</mesh_term>
	<criteria>Pathologically confirm CLL SLL require therapy Age 18 year age old ECOG performance status 0 , 1 , 2 Normal organ bone marrow function Resolution toxic effect prior therapy Ability adhere study schedule give write informed consent Any serious medical , psychiatric illness laboratory abnormality Chemotherapy radiotherapy within 4 week enter study Currently receive treatment CLL/SLL malignancy Active malignancy History allergic reaction bendamustine ofatumumab Ongoing corticosteroid use Pregnant lactating HIV positive Active hepatitis B Allogeneic transplant within 6 month enter study graftversushost disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>CLL</keyword>
	<keyword>SLL</keyword>
	<keyword>Bendamustine</keyword>
	<keyword>Ofatumumab</keyword>
</DOC>